List of Figures
Figure 1: Prostate Cancer Therapeutics, Treatment, Stages I and II 18
Figure 2: Prostate Cancer Therapeutics, Treatment, Stage III 19
Figure 3: Prostate Cancer Therapeutics, Treatment, Stage IV 27
Figure 4: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, Hormone Sensitive Disease 28
Figure 5: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, Hormone Sensitive Disease 29
Figure 6: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, First-line Treatment mCRPC 30
Figure 7: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, First-line Treatment mCRPC 31
Figure 8: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, Second-line Treatment mCRPC 32
Figure 9: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, Second-line Treatment mCRPC 33
Figure 10: Prostate Cancer Therapeutics, Global, Overview of Pipeline Products 46
Figure 11: Prostate Cancer Therapeutics, Global, Mechanisms of Action 49
Figure 12: Prostate Cancer Therapeutics, Global, Mechanisms of Action 50
Figure 13: Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2006–2015 51
Figure 14: Market Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006–2015 52
Figure 15: Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate by Mechanism of Action (%), 2006–2015 53
Figure 16: Prostate Cancer Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006–2015 54
Figure 17: Prostate Cancer Therapeutics, Global, Clinical Trial Duration by Mechanism of Action (months), 2006–2015 56
Figure 18: Prostate Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2015 58
Figure 19: Prostate Cancer Therapeutics, Global, Clinical Trial Size per Product by Mechanism of Action (participants), 2006–2015 59
Figure 20: Prostate Cancer Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006–2015 60
Figure 21: Prostate Cancer Therapeutics, Global, Clinical Trial Size of Products by Mechanism of Action (participants), 2006–2015 61
Figure 22: Prostate Cancer Therapeutics, Global, Tookad Revenue Forecast ($m), 2018–2021 64
Figure 23: Prostate Cancer Therapeutics, Global, ProstAtak Revenue Forecast ($m), 2019–2021 66
Figure 24: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Pipeline Products, Localized Disease 67
Figure 25: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Pipeline Products, Localized Disease 68
Figure 26: Prostate Cancer Therapeutics, Global, ODM-201 Forecast Revenue ($m), 2018–2021 70
Figure 27: Prostate Cancer Therapeutics, Global, Prostvac Revenue Forecast ($m), 2017–2021 72
Figure 28: Prostate Cancer Therapeutics, Global, ARN-509 Revenue Forecast ($m), 2020–2021 74
Figure 29: Prostate Cancer Therapeutics, Global, Custirsen Sodium Revenue Forecast ($m), 2017–2021 77
Figure 30: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed (Highlighted in Blue) and Pipeline Products, mCRPC – First Line 78
Figure 31: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed (Highlighted in Blue) and Pipeline Products, mCRPC – First Line 79
Figure 32: Prostate Cancer Therapeutics, Global, DCVAC Revenue Forecast ($m), 2019–2021 81
Figure 33: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed (Highlighted in Blue) and Pipeline Products, mCRPC – Second Line 83
Figure 34: Prostate Cancer Therapeutics, Global, Treatment Usage Patterns (‘000), 2014–2021 85
Figure 35: Prostate Cancer Therapeutics, Global, Market Size ($bn), 2014–2021 86
Figure 36: Prostate Cancer Therapeutics, US, Treatment Usage Patterns (‘000) and Annual Cost of Therapy ($), 2014–2021 87
Figure 37: Prostate Cancer Therapeutics, US, Market Revenue ($m), 2014–2021 88
Figure 38: Prostate Cancer Therapeutics, Canada, Treatment Usage Patterns and ACoT (‘000; $), 2014–2021 90
Figure 39: Prostate Cancer Therapeutics, Canada, Market Revenue ($m), 2014–2021 91
Figure 40: Prostate Cancer Therapeutics, Top Five European Markets, Treatment Usage Patterns (‘000), 2014–2021 92
Figure 41: Prostate Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014–2021 94
Figure 42: Prostate Cancer Therapeutics, Top Five European Markets, Market Revenue ($m), 2014–2021 95
Figure 43: Prostate Cancer Therapeutics, Japan, Treatment Usage Patterns and Annual Cost of Therapy (‘000; $), 2014–2021 97
Figure 44: Prostate Cancer Therapeutics, Japan, Market Revenue ($m), 2014–2021 98
Figure 45: Prostate Cancer Therapeutics, Global, Co-Development Deals by Region, Value and Year, 2006–2014 103
Figure 46: Prostate Cancer Therapeutics, Global, Co-Development Deals by Molecule Type, 2006–2014 104
Figure 47: Prostate Cancer Therapeutics, Global, Co-Development Deals by Molecule Type, 2006–2014 105
Figure 48: Prostate Cancer Therapeutics, Global, Licensing Deals by Value and Year, 2006–2014 108
Figure 49: Prostate Cancer Therapeutics, Global, Licensing Deals by Phase and Molecule Type, 2006–2014 109
Figure 50: Prostate Cancer Therapeutics, Global, Licensing Deals by Mechanism of Action, 2006–2014 110